Summary Homologous agglutinins demonstrated to require the simultaneous presence on erythrocytes of I and H appear to be the same as those previously called “anti‐O” or “non‐inhibitable anti‐H”. These have been termed anti‐IH. In addition, hemagglutinins with similar specificity but which are readily inhibited by soluble H substances have been termed anti‐H(‐i). Implications in regard to known problems in the typing of cord blood red cells have been mentioned. Résumé Les agglutinines homologues qui permettent de mettre en évidence sur les érythrocytes la présence simultanée I et de H semblent être les mêmes que celles qui ont été appelées précédemment «anti‐O» ou «non inhibitable anti‐H». Ceux‐ci ont été appelées anti‐IH. En outre, des hémagglutinines avec une spécificité similaire mais qui avaient la propriété d'être inhibées par les substances H solubles ont été appelées anti‐H (‐i). Les auteurs mentionnent les conséquences que peuvent avoir ces phénomènes dans la détermination des groupes sanguins des érythrocytes du sang du cordon. Zusammenfassung Diejenigen homologen Agglutinine, welche für ihre Wirkung die gleichzeitige Anwesenheit von I und H auf den Erythrozyten benütigen, sind offenbar identisch mit jenen, die bisher als «Anti‐O» bzw. als «nicht hemmbare Anti‐H» bezeichnet wurden. Sie werden als Anti‐IH bezeichnet. Hämagglutinine mit ähnlicher Spezifität, welche aber durch gelüste H‐Substanz leicht gehemmt werden, wurden als Anti‐H (‐i) bezeichnet. Die Implikationen dieser Befunde hinsichtlich der Blutgruppenanalyse von Nabelschnurerythrozyten werden diskutiert.

RATIONALE: The results of this Phase II study [EudraCT 2017-000333-31] evaluated the dose response relationship for a modified grass allergen subcutaneous immunotherapy (SCIT) product (1.0 ml) with modified allergen tyrosine adsorbate (MATA) and monophosphoryl lipid A (MPL) adjuvants for the treatment of allergic rhinoconjunctivitis (ARC) due to grass pollen. METHODS: In total 447 patients with grass pollen-induced ARC were enrolled in this randomized, double-blind, placebo-controlled, parallel group study. Patients were randomized to one of five dose regimens of 5100, 14400, 27600 and 35600 SU and placebo. As a secondary endpoint the immunoglobulin markers (total IgE, grass-specific IgE, grass-specific IgG4 and specific IgE/total IgE ratio) were evaluated. RESULTS: For all immunoglobulin markers a strong statistically significant dose-response was shown for a wide range of cumulative doses from 5100 SU to 35600 SU. Grass-specific IgE, grass-specific IgG4 and specific IgE/total IgE ratio demonstrated statistically significant increases compared to placebo for all cumulative doses (P<0.01), including the currently marketed dose of 5100 SU in Europe. CONCLUSIONS: An ultra-short course of 6 injections with allergoid grass SCIT treatment with adjuvants MATA and MPL is associated with significant increases in immunoglobulin markers for a wide range of cumulative dose levels indicating a strong therapeutic response. RATIONALE: In the U.S., subcutaneous immunotherapy (SCIT) doses are typically prepared by medical staff removing a given volume from an extract vial at a patient's injection visit. We report a novel methodology using pharmacist-prepared individual SCIT doses at an urban county hospital. METHODS: SCIT extracts are prepared by a pharmacist using dosing recommendations in the U.S. practice parameters. Individual SCIT doses are prepared by a pharmacist prior to a patient's appointment based on the patient's dosing schedule. Doses are placed in labeled syringes in patientspecific baggies. Nurses administer the pre-filled syringes to patients at their appointment. We analyzed data from January 2014 to July 2018 using this methodology. RESULTS: A total of 4203 doses were prepared; 3811 (90.6%) injections were given and 54 doses were held (1.2% of doses prepared). There were a total of 2323 patient appointments and 191 missed appointments (8% of total appointments). There were a total of 36 systemic reactions (0.9% of injections given) ranging from grade 1a -2z, with no grade 3-5 reactions. This rate of systemic reactions per injection is similar to what has been reported in the published literature of approximately 0.2% (Cox et al, 2010), and also comparable to previously reported incidences of non-fatal SCIT systemic reactions in two large cohorts. CONCLUSIONS: We describe a unique approach to delivering SCIT doses yielding a low rate of systemic reactions per injection and minimizing dosing errors. This method may be appropriate for multidisciplinary clinics with frequently changing staff to enhance patient sa...

AAAeIC pollen station, 4 Hospital de Cl ınicas, Facultad de Ciencias M edicas, UNA. Asunci on Paraguay, 5 Instituto de Previsi on Social, HCIPS. Asunci on Paraguay, 6 Hospital Privado. RATIONALE: The Poaceae constitutes a large family distributed elsewhere. This family is one of the best represented in South America, with 206 genders that includes 1523 species distributed in 10 different subfamilies. A comparison between pollination was made in 2018 in the

No abstract

RATIONALE: An unbiased investigation of age-related gene expression changes in nasal polyps (NP) may provide new treatment targets, especially for the elderly. METHODS: Affymetrix microarrays using NP tissues and control uncinate tissues (elderly, age > _65 vs non-elderly, age 18-49; n54 each group) were performed and differentially regulated genes were analyzed with a cutoff p value <0.05 and a cutoff gene expression change >2-fold. Real-time PCR (qRT-PCR), immunohistochemistry (IHS), periodic acid-Schiff (PAS) and trichrome staining were used to validate the microarray results. RESULTS: Microarray analysis identified genes regulated differentially by disease and age; 340 in NP vs controls, 446 in elderly controls vs nonelderly controls, 45 in elderly NP vs non-elderly NP, 320 in non-elderly NP vs non-elderly controls, and 190 in elderly NP vs elderly controls. qRT-PCR confirmed downregulation of PLAT (tissue-plasminogen activator-1, tPA), upregulation of SERPINE1 (plasminogen activator inhibitor-1, PAI-1) and SERPINB2 (PAI-2), and downregulation of submucosal glandrelated genes such as SCGB1D2, SCGB2A2, MUC7 and LPO (lactoperoxidase) in NP vs controls. SERPINE1 expression was significantly increased in elderly NP compared to elderly controls and PLAT expression was downregulated in non-elderly NP compared to non-elderly controls. IHC confirmed significantly reduced expression of anti-microbial proteins, MUC7 and lactoperoxidase, in NP. There was age-related reduction of serous submucosal glandular cells and relative increase of PAS-stained mucous glandular cells. Trichrome staining showed increased collagen deposition with age. CONCLUSIONS: This study demonstrates age-associated dysregulated genes in human NP, PAI-1 and tPA, which can be potential treatment targets, especially in the elderly.